Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the second quarter ended June 30, 2020. The Company also provided an update on recent business development activities and the progress of manufacturing activities related to the PPQ campaign. The Companys lead program, Vicineum, also known as VB4-845, is currently in the follow-up…
